Sales Growth YoY (Last 12 Months): Novo Nordisk A/S (NVO)

Graphic logo of novonordisk.com (NVO)

Scaling plants in Europe and the US supports colossal demand for Wegovy and Ozempic. The year-over-year sales growth percentage for TTM visualizes this expansion, where the value of 11.00 expresses the metric level. Revenue stability is based on the regular consumption of diabetes medications, which guarantees Novo Nordisk A/S (NVO) a predictable financial result and high business resilience.

Novo Nordisk AS (NVO) Revenue Growth YoY (Last 12 Months): for the period 02/11/2024 - 11/19/2026

Novo Nordisk - analytical breakdowns and key metrics (NVO)

- company stock exchange capitalization indicators:
Analysis of all company metrics:Novo Nordisk Group - NVO
Manufactured product of novonordisk.com

This indicator determines the revenue growth rate over a rolling year, excluding seasonal anomalies to provide an objective assessment of business scaling. Analyzing the rolling 12-month sales dynamics versus the same period last year allows for a comparison of financial results with the expansion of Novo Nordisk A/S (NVO) in the diabetes and obesity segments, where synergy from the acquisition of new technological platforms directly converts into accelerated operational growth.